Total trials
1,908
Active
170
Phase 3
710
Total enrollment
4,100,336
Pipeline matrix
Showing 40 of 194 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dupilumab | — | 41 | |||||
| Teplizumab | — | — | 7 | ||||
| Belumosudil | — | — | — | 6 | |||
| Fitusiran | — | — | — | — | 3 | ||
| Clotting factor concentrates | — | — | — | — | 3 | ||
| Antithrombin concentrate | — | — | — | — | 3 | ||
| Efanesoctocog alfa | — | — | — | 4 | |||
| Nirsevimab | — | — | — | 3 | |||
| Sarilumab | — | — | — | 13 | |||
| iGlarLixi | — | — | — | — | — | 2 | |
| Gla-100 | — | — | — | — | — | 1 | |
| Emicizumab | — | — | — | — | — | 1 | |
| Dexamethasone | — | 21 | |||||
| rilzabrutinib | — | — | — | — | 10 | ||
| Amlitelimab | — | — | — | 14 | |||
| Itepekimab | — | — | — | — | 7 | ||
| Frexalimab | — | — | — | — | 6 | ||
| Lunsekimig | — | — | — | — | 8 | ||
| PCV21 vaccine | — | — | — | — | — | 5 | |
| Methylprednisolone | — | — | — | 5 | |||
| Mometasone furoate nasal spray | — | — | — | — | 6 | ||
| Duvakitug | — | — | — | — | — | 4 | |
| Pomalidomide | — | — | 7 | ||||
| Diphenhydramine | — | — | 6 | ||||
| Acetaminophen | — | — | — | 5 | |||
| Montelukast | — | — | — | 4 | |||
| Yellow fever vaccine | — | — | — | 7 | |||
| Venglustat | — | — | — | — | 6 | ||
| Lenalidomide | — | — | — | 5 | |||
| RotaTeq | — | — | — | — | — | 4 | |
| Prevnar 20 vaccine | — | — | — | — | — | 3 | |
| M-M-R II vaccine | — | — | — | — | — | 3 | |
| Vaxelis vaccine | — | — | — | — | — | 3 | |
| Varivax | — | — | — | — | — | 3 | |
| Isatuximab SAR650984 | — | — | 17 | ||||
| Prednisone | — | — | — | 15 | |||
| MenACYW conjugate vaccine | — | — | — | 9 | |||
| Tacrolimus | — | — | — | 4 | |||
| Topical corticosteroids | — | — | — | — | — | 3 | |
| MRI contrast-enhancing agents | — | — | — | — | — | 2 |
154 more active programs hidden
Next readouts
- 2022-05-23
- 2022-06-24
- 2022-09-21
- 2023-03-09
- 2024-05-23
- 2024-11-06
- 2025-02-14
- 2025-10-02
- 2025-10-21
- 2025-11-05
Top conditions
- Influenza106
- Type 2 Diabetes Mellitus80
- Diabetes Mellitus, Type 278
- Diphtheria74
- Tetanus68
- Pertussis68
- Hygiene52
- Healthy Volunteers49
Frequently asked questions about Sanofi
- How many clinical trials does Sanofi have on ClinicalTrials.gov?
- Sanofi is listed as the lead sponsor on 1,908 clinical trials in ClinicalTrials.gov, 170 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sanofi's trials are in Phase 3?
- 710 of Sanofi's trials are in Phase 3, spread across 194 active drug programs.
- What therapeutic areas does Sanofi focus on?
- Sanofi's most-studied conditions on ClinicalTrials.gov are Influenza, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Diphtheria, Tetanus.
- When are Sanofi's next clinical trial readouts?
- Sanofi has 10 upcoming primary-completion readouts tracked here; the soonest is “Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia”, expected around 2022-05-23.